RESEARCH ARTICLE

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines

Anne Julienne Genuino1,2, Usa Chaikledkaew1,3*, Anna Melissa Guerrero2, Thanyanan Reungwetwattana4 and Ammarin Thakkinstian1,5

Abstract

Background: Breast cancer is the leading malignancy among Filipino women, with about 23.50% of cases characterized by human epidermal growth factor receptor-2 (HER2) overexpression. Trastuzumab, in addition to standard chemotherapy, is currently recommended as primary treatment for HER2-positive early-stage breast cancer (EBC) in the adjuvant settings, and has been listed in the Philippine National Formulary (PNF) since 2008, but with no current evidence yet on its value for money, to date. Hence, despite several policy enablers, its accessibility remains to be limited in the Philippines. We performed an economic evaluation to assess the cost-effectiveness and budget impact of adjuvant trastuzumab therapy for HER2-positive EBC in the Philippines, using healthcare system and societal perspectives, in aid of guiding coverage decisions.

Methods: A Markov model-based cost-utility and budget impact analyses were conducted to estimate the total costs incurred and outcomes gained in using 1 year of adjuvant trastuzumab added to standard chemotherapy versus standard chemotherapy alone, over a lifetime horizon. We discounted both costs and outcomes at 3.5% per annum. Parameters were estimated using country survival data, systematic review and meta-analysis of the relative treatment effect, local and international cost data, and published utility data. Univariate and probabilistic sensitivity analyses were used to account for parameter uncertainty.

Results: Trastuzumab therapy was dominated with an incremental cost-effectiveness ratio (ICER) at PHP 453,505 per QALY gained from a healthcare system perspective or PHP 458,686 per QALY gained from a societal perspective, with 10% cost-effectiveness probability at the country cost-effectiveness threshold of PHP 120,000 per QALY gained. National implementation will cost an additional amount of PHP 13,909 million in year one alone, plus about PHP 2000 to 3000 million annually for the succeeding fiscal years.

Conclusion: At its current cost, 1 year of adjuvant trastuzumab therapy compared to standard chemotherapy alone for HER2-positive EBC does not represent value for money in the Philippines. Its current cost will have to significantly lower down by one-half to achieve cost-effectiveness.

Keywords: Adjuvant trastuzumab, Cost-utility analysis, HER2-positive, Breast cancer, Cost-effectiveness, Philippines
Background

Breast cancer is currently the globally leading malignancy among women with about 1.7 million diagnosed cases and 521,907 deaths as estimated by the World Health Organization (WHO) in 2012 [1]. In the Philippines, it is recognized as the most prevalent cancer among women and in both sexes, as well as the most common cause of cancer deaths among women [2]. About 15 to 20% of breast cancers overexpresses human epidermal growth factor receptor-2 (HER2) [3] – a clinically important subtype of breast cancer that is associated with an aggressive disease phenotype and shortened survival outcomes [4], resulting in poorer prognosis compared to other subtypes. Two large studies of breast cancer data in the United States [5][6] reported, however, that women of Asian descent were more likely to have HER2-positive tumours than Caucasian women suggesting possible racial differences. In the Philippines, the Department of Health (DOH) Breast Cancer Control Program reported a HER2-positivity rate of 23.17%, with an estimated 80% of them at the early stage [7, 8].

The discovery of revolutionary therapies such as trastuzumab, the first monoclonal antibody to specifically target HER2, has changed the course of treatment and improved the prognosis of affected breast cancer patients. Several key pivotal trials have demonstrated its relative treatment efficacy versus standard chemotherapy alone, in improving the disease-free and overall survival of HER2-positive early-stage breast cancer (EBC) patients [9–16]. These same trials though have reported an associated increased risk for cardiotoxic effects such as congestive heart failure (CHF) and left ventricular ejection fraction (LVEF) decline [9–16].

Both global [17, 18] and national clinical guidelines [19] currently recommend the administration of trastuzumab with chemotherapy regimens as primary treatment for HER2-positive EBC in adjuvant settings. It has been listed in the Philippine National Formulary (PNF) since 2008, but with no current evidence yet on its value for money to date. Hence, despite several policy enablers, its accessibility remains to be limited as the current government insurance case rate for breast cancer does not cover the treatment for HER2-positive type; public hospitals cannot afford to procure and make it available in their facilities due to its high cost; and, while it has been recently included in the list of subsidized medicines under the DOH Breast Cancer Medicine Access Program (DOH BCMAP) under a negotiated reduced price for national hospitals, the access sites and medicine stocks are limited.

Assessing cost-effectiveness is critical in establishing equitable trade-off decisions between the sustainable access to such effective health technology that can improve survival and the limited health budget, especially for resource-constrained countries such as the Philippines. While many published economic evaluation (EE) studies have been previously conducted to assess its cost-effectiveness, all were conducted in settings that are not comparable to a lower-middle income country (LMIC) like the Philippines, as they were all from upper-middle and high-income countries [20–35]. Therefore, we conducted this economic evaluation to assess the cost-effectiveness and budget impact of adjuvant trastuzumab therapy compared to chemotherapy regimen alone for patients with HER2-positive EBC in the Philippines, to guide coverage decisions.

Methods

We conducted a cost-utility analysis (CUA) using decision analytic Markov model to calculate and compare the costs and utilities of using 1 year of adjuvant trastuzumab combined with standard chemotherapy (i.e., doxorubicin 60 mg/m² on day 1 plus cyclophosphamide 600 mg/m² on day 1 every 3 weeks for 4 cycles followed by docetaxel 100 mg/m² on day 1 plus trastuzumab 8 mg/kg initial dose then 6 mg/kg on day 1 every 3 weeks for 4 cycles then trastuzumab 6 mg/kg on Day 1 every 3 weeks for 14 cycles) versus chemotherapy alone (i.e., same chemotherapy minus trastuzumab) for Filipino women with HER2-positive EBC. The model cohorts were Filipino women with HER2-positive EBC who enter the model at the age of 50 years old which is the mean age of patients enrolled in the Department of Health Breast Cancer Medicines Access Program (DOH BCMAP) [36]. We modelled over a lifetime horizon from both publicly-funded healthcare system and societal perspectives, with a discounting rate of 3.5% per year applied to both costs and outcomes. We measured the incremental cost-effectiveness ratio (ICER) as Philippine Peso (PHP) per Life Year (LY) or Quality-adjusted life year (QALY) gained. We applied the current Philippine cost-effectiveness threshold value of PHP 120,000 per QALY gained that was set by the Formulary Executive Council in the Philippines based on the value of one times Gross Domestic Product (GDP) per capita in the Philippines. In the case that trastuzumab was not cost-effective, a threshold analysis was performed to calculate the cost-effective price of trastuzumab therapy. Further, we estimated the likely budget impact of its national coverage for five fiscal years.

Model overview

Our model structure as illustrated in Fig. 1 consists of five health states - disease-free survival (DFS), congestive heart failure (CHF), local recurrence, distant metastasis,
and death. Upon administration of either of the competing interventions, the cohort enters the model at the DFS state. We applied a cycle length of 1 year which was run for 49 cycles to represent lifetime horizon. The model assumed that patients who progressed to CHF could only experience it once as cardiotoxicity from trastuzumab is only an asymptomatic decline in LVEF and is mostly reversible with interruption of trastuzumab or cardiac medication [37]. From CHF state, they have the option to move to DFS, local recurrence, or distant metastasis state.

It was also assumed that the cohort does not have any baseline co-morbidities and the use of hormonal therapies was not considered. Based on the methodological domains and assumptions, a spreadsheet model was developed using Microsoft Office Excel 2013 (Microsoft Corp., Redmond, WA) to generate the total lifetime costs incurred and LYs or QALYs gained through cohort simulation.

Model input parameters

Clinical data

The primary data source for the baseline TPs between the health states was obtained from published literatures [31, 38], which were estimated from the four-year follow-up of joint analysis of data from NCCTG N9831 and NSABP B-31 trials on the efficacy and safety trastuzumab plus standard anthracycline-taxane-based CT [39].

We generated the relative treatment effect of trastuzumab by conducting a systematic review and meta-analysis of published trials [9–16] on the efficacy and safety of adjuvant trastuzumab [40]. The benefit of trastuzumab was incorporated in the model as a reduction applied in the risk of developing local recurrence, distant metastasis, and mortality for the intervention model cohort when at DFS state. As for the longest follow-up data available to date showing constant treatment effect over 11 years [9], it was therefore assumed that the efficacy of trastuzumab lasts for 11 years. The cardiotoxic effect was incorporated in the model as increased risk for CHF for the intervention model cohort.

Utility data

The utility values associated with the model health states were sourced from a quality of life study among 30 patients each with early and advanced breast cancers at Hanoi Oncology Hospital and Da Nang Oncology Hospital Vietnam [41], which were derived using the EuroQol five-dimensional with three-level (EQ-5D-3L) questionnaires. As the only utility weight study derived from an Asian population in a fellow LMIC setting to date, it was deemed that Vietnam utilities are comparable and applicable to the Philippine setting.

Cost data

Direct medical costs (DMC) were comprised of work-up, treatment and monitoring costs related to laboratory and diagnostic tests, procedures, admissions and outpatient visits, and pharmacologic therapy. A pre-constructed costing sheet guided by clinical guidelines [18, 42, 43] was consulted among local experts. We then valuated the final costing items using the government standard case rate values [44] and data from a local costing study [45] for the medical services, procedures, and diagnostics; and, the government drug price reference index [46] and procurement data [47] for all drug costs. The cost per vial of trastuzumab was based on the negotiated price under the DOH BCMAP for
the 150 mg-IV-vial preparation amounting to PHP 619,667 for all trastuzumab cycles. The dose calculation was based on a 65 kg-body weight. All costs were expressed in PHP 2017 values and inflation adjustments were applied as necessary by using the Consumer Price Indexes (CPI) [48].

Direct non-medical costs (DNMC) were estimated using the costing values for food and transportation expenses from the Thai Standard Costing Lists for Health Economic Evaluation [49], in the absence of these standard costing values in the Philippines. These costs (in 2009 Thai Baht values) were converted to 2017 PHP values by using the 2009 conversion factors 1 USD = 33.129 Thai Baht [50] and 1 USD = PHP 46.421 [51], then adjusted for inflation using CPI [48]. The utilization of such costs was assumed to incur for every health facility visit involved relevant for the particular health state. The list of all input parameters used in the model is summarized in Table 1.

Sensitivity analysis

Both one-way and probabilistic sensitivity analyses (PSA) using second order Monte Carlo simulation replicated for 50,000 times were performed to handle parametric uncertainties. We assigned beta distribution for TPs and utility parameters; log-normal distribution for the relative treatment effect; and, gamma distribution for cost parameters. The PSA results were illustrated as incremental cost-effectiveness planes and cost-effectiveness acceptability curves. A discount rate of 0 to 6%, and a treatment efficacy duration of 5 years to 49 years were also applied in the one-way sensitivity analysis.

Results

Cost-effectiveness analysis

Based on a probabilistic approach, from the healthcare system perspective, trastuzumab therapy compared to chemotherapy alone was estimated to incur an additional cost of PHP 452,128 with an expected health gain of additional 1.20 LY or 1.00 QALY per patient, resulting in an ICER of PHP 377,009 per LY gained, or PHP 453,505 per QALY gained. From a societal perspective, adopting adjuvant trastuzumab therapy was estimated to cost an additional PHP 457,131 for a similar additional health benefit, resulting to an ICER of PHP 381,405 per LY gained, or PHP 458,686 per QALY gained.

The ICERs from both perspectives have consistently shown that adding 1 year of adjuvant trastuzumab to chemotherapy for HER2-positive EBC is not cost-effective in the Philippines as they exceeded the cost-effectiveness threshold by about 3.8 times more. The lifetime costs, LYs and QALYs gained from using trastuzumab therapy versus chemotherapy alone, and the resulting ICERs in the probabilistic analysis from the two perspectives are shown in Table 2.

Threshold sensitivity analysis

Results have shown that the cost-effective price of adjuvant trastuzumab therapy per patient is PHP 596,239 from the healthcare system perspective, or PHP 590,314 from a societal perspective. This implies that the current cost of adjuvant trastuzumab therapy overall, including the cost of standard chemotherapy drugs and other supportive medications, chemotherapy administration cost and cardiac function tests (i.e., PHP 1,076,607), needs to be decreased further by about one-half in order to achieve an ICER that will be at least equal to the cost-effectiveness threshold.

Probabilistic sensitivity analysis

The results the Monte Carlo simulation with 50,000 replications were plotted in a cost-effectiveness plane, presented in Fig. 2. Majority of the ICER plots appear at the upper-right hand quadrant of the plane extending to form an ellipsoid shape which implies the positive correlation of the incremental cost and the incremental outcomes. The black line represents the resulting mean ICER while the green line represents the cost-effectiveness threshold where estimates below this line are considered cost-effective.

Figure 3 presents the cost-effectiveness acceptability curve for the healthcare system. Transforming the results of the CE plane to a cost-effectiveness acceptability curve as illustrated in Fig. 3 demonstrates that at the cost-effectiveness threshold of PHP 120,000 per QALY gained (green line), the probability of cost-effectiveness of adjuvant trastuzumab therapy is 10%, while that for the chemotherapy alone regimen is 90%, under both perspectives. The current cost-effectiveness threshold has to increase by about four times more (i.e., PHP 500,000 per QALY gained) in order for adjuvant trastuzumab to reach at least 48% probability of cost-effectiveness from the publicly-funded healthcare system perspective, or 51% probability of cost-effectiveness from the societal perspective. The trastuzumab curve only started to rise steeply as the threshold increases at PHP 650,000 per QALY gained.

Deterministic sensitivity analysis

The results of the one-way sensitivity analyses are presented in Fig. 4. Among all input parameters varied under both perspectives, the ICER results were most sensitive to variations in the hazard ratio for DFS, duration of efficacy of trastuzumab, discounting rate for outcomes, cost of trastuzumab therapy, and TP from DFS to metastasis state. On the other hand, the model estimates were negligibly sensitive with respect to
Table 1 Input parameters used in the model and their sampling distribution for the probabilistic sensitivity analysis

| Parameter | Mean (SE) | Distribution | Source |
|-----------|-----------|--------------|--------|
| Clinical Parameters | | | |
| **Baseline Transitional Probabilities** | | | |
| DFS ➔ CHF | 0.0053 (0.0024) | Beta | Buendia et al., 2013 [31] |
| DFS ➔ Recurrence | 0.0294 (0.0029) | Beta | |
| DFS ➔ Metastasis | 0.0785 (0.0140) | Beta | |
| DFS ➔ Death | 0.0020 (0.0001) | Beta | |
| CHF ➔ Recurrence | 0.0294 (0.0029) | Beta | |
| CHF ➔ Metastasis | 0.0785 (0.0140) | Beta | |
| CHF ➔ Death | 0.1500 (0.0153) | Beta | Dokainish et al., 2017 [52] |
| Recurrence ➔ Metastasis | 0.0785 (0.0140) | Beta | Buendia et al., 2013 [31] |
| Recurrence ➔ Death | 0.2950 (0.2066) | Beta | |
| Metastasis ➔ Death | 0.2950 (0.2066) | Beta | |
| **Relative treatment efficacy of adjuvant trastuzumab therapy** | | | |
| Pooled hazard ratio for DFS | 0.65 (0.0825) | Log-Normal | Genuino et al., 2019 [40] |
| Pooled hazard ratio for OS | 0.67 (0.0493) | Log-Normal | |
| Pooled risk ratio for CHF | 3.97 (0.2240) | Log-Normal | |
| **Epidemiological Data** | | | |
| 5 – year prevalence of Breast Cancer in the Philippines | 64,046 prevalent cases | – | WHO GLOBOCAN, 2012 [8] |
| Incidence of Breast Cancer in the Philippines | 21,057 new cases | – | Estimated based on the 2015 new cases (Philippine Cancer Facts and Estimates, 2015 [2]) adjusted to 2017 values by applying the incidence rate calculated using the total population for 2015 [53] and 2017 [54] |
| Percentage of HER2-positivity of breast cancer in the Philippines | 23.17% | – | DOH Breast Cancer and Control Program, 2013 [7] |
| Estimated percentage of early-stage HER2-positive breast cancer cases in the Philippines | 80% | – | DOH Breast Cancer and Control Program, 2013 [7] |
| **Cost Parameters** | | | |
| DMC of adjuvant trastuzumab therapy for the intervention cohort (per patient per treatment course) – Drugs, CT administration, cardiac function assessment | PHP 107,660 (54,929) | Gamma | DOH Philippines -Pharmaceutical Division, 2018 [47] |
| DMC of adjuvant CT for the control cohort (per patient per treatment course) – Drugs, CT administration, cardiac function assessment | PHP 194,900 (99,444) | Gamma | Philippine Health Insurance Corporation, 2013 [44] |
| DNMC of adjuvant treatment for intervention cohort | PHP 9,432 (481) | Gamma | Riewpaiboon, 2014 [49] |
| DNMC adjuvant treatment for control cohort | PHP 3,494 (178) | Gamma | |
| DMC at DFS state - imaging, labs, visits/consultation | PHP 9,493 (484) | Gamma | Wong, 2018 [45] |
Table 1 Input parameters used in the model and their sampling distribution for the probabilistic sensitivity analysis (Continued)

| Parameter | Mean (SE) | Distribution | Source |
|-----------|-----------|--------------|--------|
| DNMC at DFS state | PHP 1747 (80) | Gamma | Riewpaiboon, 2014 [49] |
| DMC at CHF state - hospital admission, echocardiography, drugs, cardiac monitoring | PHP 3400 (1602) | Gamma | Philippine Health Insurance Corporation, 2013 [44] |
| DNMC at CHF state | PHP 1049 [48] | Gamma | Riewpaiboon, 2014 [49] |
| DMC at Local Recurrence state (first year) - work-up, radiotherapy, CT drugs, CT administration | PHP 567156 (3061) | Gamma | DOH Philippines, 2018 [46] |
| DMC at Local Recurrence state (first year) | PHP 8166 (1488) | Gamma | Riewpaiboon, 2014 [49] |
| DMC at Local Recurrence state (after first year) - CT drugs, CT administration | PHP 182437 (15513) | Gamma | DOH Philippines, 2018 [46] |
| DNMC at Local Recurrence state (after first year) | PHP 17817 (178) | Gamma | Riewpaiboon, 2014 [49] |
| DMC at Local Recurrence state (after first year) - CT drugs and administration | PHP 516904 (26373) | Gamma | DOH Philippines, 2018 [46] |
| DNMC at Local Recurrence state (after first year) | PHP 5939 (273) | Gamma | Riewpaiboon, 2014 [49] |
| DMC at Distant Metastasis state (first year) - work-up, radiotherapy, CT drugs, CT administration, palliative care drugs | PHP 956172 (48784) | Gamma | DOH Philippines, 2018 [46] |
| DNMC at Distant Metastasis state (first year) | PHP 10131 (465) | Gamma | Riewpaiboon, 2014 [49] |
| DMC at Distant Metastasis state (after first year) - CT drugs and administration, palliative care drugs | PHP 1666816 (59531) | Gamma | DOH Philippines, 2018 [46] |
| DNMC at Distant Metastasis state (after first year) | PHP 5939 (273) | Gamma | Riewpaiboon, 2014 [49] |

Utility Parameters

| DFS | 0.8320 (0.0084) | Beta | Ahn et al., 2014 [41] |
| CHF | 0.6700 (0.272.71) | Beta |
| Recurrence | 0.8280 (0.0262) | Beta |
| Metastasis | 0.7620 (0.0262) | Beta |

Table 2 Cost-effectiveness results of probabilistic sensitivity analysis

| Healthcare system perspective | Trastuzumab-CT regimen | CT only regimen | Difference |
|------------------------------|------------------------|----------------|------------|
| Total Lifetime Cost (PHP)    | 4,462,407              | 4,010,279      | 452,128    |
| Total LYs gained             | 11.07                  | 9.87           | 1.20       |
| Total QALYs gained           | 8.99                   | 7.99           | 1.00       |
| ICER (PHP per LY gained)     | 377,009                |                |            |
| ICER (PHP per QALY gained)   | 453,505                |                |            |
variations in the DMC and DNMC for all health states, and all utilities at the different health states. The yellow bars show the effect on the ICER of applying the lower limit of the specific parameter, while the green bars show the effect on the ICER of applying the upper limit of the specific parameter.

We likewise explored the impact on the cost-effectiveness of adjuvant trastuzumab therapy of simultaneous changes in the values of the HR of DFS and the duration of efficacy. The two-way sensitivity analysis as illustrated in Fig. 5 shows that over the plausible range of the said parameters, standard chemotherapy remained the cost-effective approach.

Budget impact analysis
The estimated number of prevalent cases of HER2-positive EBC in the Philippines is 11,872 which was calculated based on the estimated proportion of early-stage cases (i.e., 80% [7]) among all HER2-positive patients which is about 23.17% (i.e., HER2-positivity rate in the Philippines [7]) of the total breast cancer prevalent cases in the country [8]. The same calculation was performed for the generation of the estimated new cases of 3903 by calculating the proportions of early-stage HER2-positive cases from the total breast cancer new cases in the Philippines [2] adjusted to 2017 value.
The total budget for implementing adjuvant trastuzumab therapy to cover all estimated prevalent and new cases of HER2-positive EBC patients in the Philippines will demand high health budget as it will incur PHP 16,983 million per cohort in year one alone, plus more than PHP 5200 million annually per cohort on the next four fiscal years. On the contrary, implementing chemotherapy alone to cover the same number of prevalent and new cases will incur a total cost of PHP 3075 million in year one, and more than PHP 2300 million annually on the next four fiscal years. The incremental budget, therefore, is about PHP 13,909 million in year one alone, plus about PHP 2000 to 3000 million annually on the next four fiscal years, as presented in Fig. 6.

**Discussion**

To our knowledge, this is the first published study in Philippines and among LMICs to evaluate the health and economic impact of adjuvant trastuzumab therapy for HER2-positive EBC. The study is intended to guide coverage decisions on such effective but high cost therapy under a low-resource setting. It is believed that this economic evaluation faithfully considered and represented all the best available evidence appropriate to a developing country context by conducting a systematic review and meta-analysis to estimate the relative treatment effect.

In this model, we project that shifting to 1 year of adjuvant trastuzumab therapy in addition to chemotherapy
for HER2-positive EBC, at its current cost, shall incur additional cost to the government of PHP 453,505 or USD 9084, or the society with additional PHP 458,686 or USD 9188 (2017 Exchange Rate: 1 USD = PHP 49.9230 [51]) for every unit of QALY gained. Exceeding the cost-effectiveness threshold by 3.8 times more, our findings suggest that such therapy is not cost-effective in the Philippines with 10% of being cost-effective at the threshold compared to chemotherapy alone at 90%. Its value for money will improve if its current therapy cost will reduce by one-half. Apart from cost-effectiveness, the decision makers will also have to consider the affordability of trastuzumab coverage. The total acquisition cost for trastuzumab drug alone for a national coverage implementation will cost about PHP 7.36 billion – an amount that significantly exceeds the usual annual budget for the procurement of various breast cancer medicines covered under the DOH BCMAP (i.e., ranging from PHP 39 to 92 million from year 2009 to 2017) and can consume the chunk of the DOH budget allocation for the procurement of all drugs under the national health programs (i.e., PHP 9.87 billion for 2018) [55, 56].

Our generalizations are comparable with majority of previous EEs from upper-middle-income countries (UMICs) [31–33] which similarly concluded that trastuzumab in their settings is not cost-effective. In Iran [33], the ICER is about USD 174,901 per QALY gained which is 17 times more than its cost-effectiveness threshold. The ICERs range from about USD 63,036 to 174,901 in Latin American countries [31, 32], similarly exceeding their cost-effectiveness threshold by 6 to 15 times more. On the contrary, the CUA studies from high-income countries (HICs) [20–24, 26–30, 34, 35] concluded that trastuzumab is cost-effective in their settings with their ICERs ranging from USD 11,334 to 78,929 per QALY gained. Trastuzumab though was found to be cost-effective in the analyses from two UMICs specifically in China by Chen et al., 2009 [25] and in Thailand by Kongsakon et al., 2018 [38], with ICERs at USD 9976 per QALY gained and USD 6527 per QALY gained, respectively. Such relatively lower ICER and opposing conclusion compared to the earlier mentioned findings from majority of analysis from UMICs [31–33] may be explained by several factors. Chen et al., 2009 applied a relatively lower hazard ratio (i.e., 0.54) versus those used by the studies in Iran (i.e., 0.64) and Latin America (i.e., 0.59). Second, it applied a 5-year efficacy duration with decreasing efficacy in a stepwise function, compared to the studies in Iran and Latin America which applied a 5-year duration of efficacy with zero applied benefit onwards. Kongsakon et al., 2018 [38] did not incorporate cardiac events in their modelling analysis which may have resulted to an underestimated ICER.

Considering ICER values alone, our ICERs (~ USD 9084 per QALY gained) were in fact lower than the ICER range from UMICs (USD 63,036 to 174,901 per QALY gained) which concluded for non-cost-effectiveness [31–33], the ICER range from HICs (USD 11,334 to 78,929 per QALY gained) which concluded for cost-effectiveness [20–24, 26–30, 34, 35]. Two factors in this analysis may have contributed to our relatively low ICER: First is the longer duration of trastuzumab efficacy applied in this modelling (i.e., 11 years) versus most of the previous studies (i.e., 5 years) which was based on the currently available follow-up data during the time of those EEs; and, second is the
lower cost of trastuzumab therapy in our analysis (USD 12,412) versus other studies (USD 35,349 to 137,677). Our low ICER, however, did not automatically translate to favourable cost-effectiveness findings because of the relatively low Philippine cost-effectiveness threshold at USD 2,404 per QALY gained only, compared to the higher thresholds of UMICs (~USD 5000 to 15,000 per QALY gained) and HICs (USD 37,920 to 354,555).

Our results were specifically sensitive to the following parameters i.e., the relative treatment efficacy which underscores the significance of estimating the effectiveness from real-world data where a less favourable treatment effect in the actual clinical practice setting may be possibly observed compared to follow-up studies under controlled environment; the duration of clinical efficacy which supports the significance of longer follow-up data on trastuzumab to define its real duration of benefit, and therefore its value for money; and, the cost of trastuzumab therapy which emphasizes the need to consider schemes to bring down its incurred cost to the government in order to achieve cost-effectiveness. Nevertheless, the model and its overall findings proved to be relatively robust, showing minimal sensitivity with variations in the majority of the parameters.

There were several limitations in this analysis. First, we referred to the Vietnamese utility data for breast cancer in the absence of such data in the Philippines. While there may be differences between Filipinos and Vietnamese patients on the valuation of health states because of numerous factors (e.g., cultural differences affecting disease perception, social support, health system structure), this approach was deemed acceptable because of a comparable Asian context and economic status. Second, we used the Thai cost values for the DNMCs in the societal perspective analysis due to data unavailability. As the only available and accessible standard costing menu from a similar Asian setting, using the Thai cost values was likewise deemed acceptable. The recommended study perspective anyway in the Philippine methods guide for economic evaluation is publicly-funded healthcare system which, in our analysis, used purely local costing data. Lastly, the estimation of baseline TPs were obtained from published data, not local data. Hence, it is recommended in future analysis to re-run the modelling using local TPs, health utilities and DNMC values. Exploring the role of subgroups (i.e., hormone-receptor and nodal status) on the value for money of trastuzumab is likewise proposed.

Conclusion
In conclusion, this CUA suggests that 1 year of adjuvant trastuzumab therapy, at its current cost, in addition to the standard chemotherapy for HER2-positive EBC, might not be cost-effective and unaffordable in the Philippines. The government should consider schemes to lower down the cost to improve its value for money such as price negotiation, facilitation of the entry of cheaper biosimilar products, or targeted coverage (for the worst prognosis subtype or high risk subgroups), ultimately towards sustainable access to trastuzumab.

Our findings are designed to aid policy decisions of a resource-constrained setting on the coverage of such effective but high cost therapy. As this research is the first published study among LMICs to evaluate the health and economic impact of adjuvant trastuzumab therapy for HER2-positive EBC, our findings may guide decision-makers from comparable low resource settings with low capacity to conduct economic evaluations who are also facing a similar policy and research question.

Abbreviations
CHF: Congestive heart failure; CPI: Consumer price index; CT: Chemotherapy; CUA: Cost-utility analysis; DMC: Direct medical cost; DNMC: Direct non-medical cost; DOH BCMAP: Department of Health Breast Cancer Medicine Access Program; DOH: Department of Health; EBC: Early stage breast cancer; EE: Economic evaluation; HER2: Human epidermal growth factor receptor 2; HIC: High income country; HR: Hazard ratio; ICER: Incremental cost-effectiveness ratio; LMIC: Lower-middle income country; LVEF: Ventricular ejection fraction decline; LY: Life year; OS: Overall survival; PCS: Philippine Cancer Society; PHL CE threshold: Philippine cost-effectiveness threshold; PHP: Philippine Peso; PNF: Philippine National Formulary; PSA: Probabilistic sensitivity analysis; QALY: Quality adjusted life year; RR: Risk ratio; TP: Transition probability; UMIC: Upper-middle income country; WHO: World Health Organization

Acknowledgements
The authors are grateful to the Pharmaceutical Division and the National Breast Cancer Control Program of the DOH Philippines, and to Dr. Rachel Rosario and Mr. Romeo Marcaida of the PCS.

Authors’ contributions
AJG performed the research, analysed data and drafted manuscript. UC designed the research, validated and interpreted data, as well as drafted manuscript. AW designed the research and drafted manuscript. TR and AT interpreted clinical data and drafted manuscript. All authors have agreed and approved the author’s contribution and final manuscript.

Funding
Our study was not supported by a pharmaceutical company. This work is a part of training in Health Technology Assessment (HTA)’s Master degree, which scholarship is provided by Mahidol University and the International Decision Support Initiative (iDSI). This work was produced as part of the International Decision Support Initiative (www.idsihealth.org), which supports countries to get the best value for money from health spending. iDSI receives funding support from the Bill & Melinda Gates Foundation, the UK Department for International Development, and the Rockefeller Foundation. The funding agencies of this study have no role in study design, data collection, data analysis, findings, interpretations, conclusions or writing of this manuscript.

Availability of data and materials
The patient data that support the findings of this study are available from the DOH and PCS but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the DOH and PCS.
Ethics approval and consent to participate
The Faculty of Dentistry/ Faculty of Pharmacy, Mahidol University, Institutional Review Board reviewed the protocol and granted the ethics approval to access the available aggregated patient data from the PCS, owned by the DOH Philippines. The DOH Philippines also released a certification, to allow the use of the aggregated survival data for the sole purpose of this study.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Bangkok, Thailand. 2Pharmaceutical Division, Department of Health Philippines, Manila, Philippines. 3Social and Administrative Pharmacy Excellence Research (SAPER) Unit, Department of Pharmacy, Faculty of Medicine, Mahidol University, 447 Sri-Ayutthaya Rd, Phayathai, Ratchathewi, Bangkok 10400, Thailand. 5Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 6Section for Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Bangkok, Thailand.

Received: 9 May 2019 Accepted: 6 November 2019
Published online: 21 November 2019

References
1. Cancer WHO-IARo. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [web page]. World Health Organization; 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 15 Dec 2018.
2. Laudico AVM-LM, Medina V, Mapua G, Valenzuela F, Fukala E, Philippine breast cancer facts and estimates. Manila: Department of Health – Disease Prevention and Control Bureau; 2015.
3. Wolff ACHM, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Blouin M, Fitzgibbons F, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/Collage of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.
4. Gajj D, Chandralapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011;11(2):263–75.
5. Kwan MLK, Weltzien E, Maring B, Kuter SE, Fulton RS, Lee MM, Ambrosone CB, Cao BJ. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009;11(3):R31.
6. Parise CABK, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California. 1999-2004. Breast J. 2009;15(6):593–602.
7. Philippines DOH-NBCCP. National breast cancer control program - HER2 testing census. In: Bureau DOH-DPA, editor. 2013.
8. Organization WH. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [ARC]. Lyon: World Health Organization; 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. cited 2012.
9. Cameron DP-GM, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–205.
10. Perez EAR, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martin SW, Rostogi P, Gralow J, Swain SM, Winer EP, Colón-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9833. J Clin Oncol. 2014;32(31):3781–9.
